Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

72.20 +2.48 (+3.56%)
Streaming Delayed Price Updated: 11:03 AM EDT, Aug 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 76,161
Open 70.24
Bid (Size) 72.13 (1)
Ask (Size) 72.28 (1)
Prev. Close 69.72
Today's Range 70.13 - 72.32
52wk Range 43.46 - 116.60
Shares Outstanding 59,719,570
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Where Blueprint Medicines Stands With Analysts
Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings: 
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
-34.41%
-34.41%
1 Month
+31.02%
+31.02%
3 Month
+33.64%
+33.64%
6 Month
-13.19%
-13.19%
1 Year
-24.17%
-24.17%

More News

Read More
Blueprint Medicines: Q2 Earnings Insights
Via Benzinga
A Preview Of Blueprint Medicines's Earnings
Via Benzinga
3 Biotech Stock Picks From This Wedbush Analyst
Via Benzinga
4 Analysts Have This to Say About Blueprint Medicines
Via Benzinga
Blueprint Medicines: Q1 Earnings Insights
Via Benzinga
Week In Review: Qiming Closes $3.2 Billion For China Healthcare And Technology Investments
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022
Via Benzinga
This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation'
Via Benzinga
What 7 Analyst Ratings Have To Say About Blueprint Medicines
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022
Via Benzinga
SVB Leerink Maintains Market Perform Rating for Blueprint Medicines: Here's What You Need To Know
Via Benzinga
10 Biggest Price Target Changes For Monday
Via Benzinga
91 Biggest Movers From Friday
Via Benzinga
44 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022
Via Benzinga
What You Missed On Wall Street On Thursday
Via Talk Markets
Blueprint Stock Dives On The FDA's Tricky New Requirement For Its Leading Drug
Via Investor's Business Daily
Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead?
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Via Benzinga
What 3 Analyst Ratings Have To Say About Blueprint Medicines
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Via Benzinga
Earnings Preview: Blueprint Medicines
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.